Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -413,840 | -259,336 | -210,960 | -156,730 | -107,431 |
| Depreciation Amortization | 377 | 231 | 193 | 126 | 65 |
| Accounts receivable | 3,232 | -4,577 | 11,764 | -11,633 | -596 |
| Accounts payable and accrued liabilities | 10,939 | 5,455 | -16,968 | 16,430 | 1,251 |
| Other Working Capital | -12,031 | 2,632 | -10,853 | 15,142 | 4,566 |
| Other Operating Activity | 35,449 | 41,368 | 38,631 | 30,553 | 18,818 |
| Operating Cash Flow | $-375,874 | $-214,227 | $-188,193 | $-106,112 | $-83,327 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -759 | -360 | -197 | -254 | -210 |
| Investing Cash Flow | $-759 | $-360 | $-197 | $-254 | $-210 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 200,000 | N/A |
| Common Stock Issued | 454,811 | 478,439 | 71,157 | N/A | 386,442 |
| Other Financing Activity | -319 | -6,012 | -272 | 129 | -3,330 |
| Financing Cash Flow | $454,492 | $472,427 | $70,885 | $200,129 | $383,112 |
| Exchange Rate Effect | 747 | 993 | 220 | -92 | N/A |
| Beginning Cash Position | 635,365 | 376,532 | 493,817 | 400,146 | 100,571 |
| End Cash Position | 713,971 | 635,365 | 376,532 | 493,817 | 400,146 |
| Net Cash Flow | $78,606 | $258,833 | $-117,285 | $93,671 | $299,575 |
| Free Cash Flow | |||||
| Operating Cash Flow | -375,874 | -214,227 | -188,193 | -106,112 | -83,327 |
| Capital Expenditure | -759 | -360 | -197 | -254 | -210 |
| Free Cash Flow | -376,633 | -214,587 | -188,390 | -106,366 | -83,537 |